Related Experiment Video
Updated: Jan 7, 2026

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
Published on: February 15, 2022
A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative
Connie Pei Chen Ow1, Rachel M Peiris1, Anton Trask-Marino1
1Translational Cardiovascular and Renal Research Group and Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, 30 Royal Parade, Parkville, 3052, Melbourne, VIC, Australia.
Background:
Megadose sodium ascorbate has shown promise as a treatment to reverse the pathophysiological effects of ovine Gram-negative sepsis. In human septic shock, lower doses of sodium ascorbate improved urine output and reduced vasopressor requirements compared with placebo. We sought to determine the minimum therapeutic dose of sodium ascorbate required to reverse sepsis-induced cardiovascular and renal dysfunction in sheep.
Methods:
Healthy young adult sheep were instrumented with renal artery flow probes, and oxygen-sensing and laser Doppler probes in the kidneys. Non-anaesthetised animals were infused with live Escherichia coli for 31-h. At 23.5-h of sepsis, four groups (n = 7-8/group) received fluid resuscitation (30 mL/kg Hartmann's solution) and were randomized to intravenous sodium ascorbate (1.0, 2.0, or 3.0 g/kg) or vehicle, delivered as a bolus followed by 7-h infusion. Norepinephrine was titrated to maintain mean arterial pressure (MAP) at ~ 70 mmHg.
Results:
At 23-h of sepsis, animals developed hypotension, hyperlactatemia, acute kidney injury, and renal medullary hypoxia. Vehicle-treated sheep required escalating doses of norepinephrine (from 0.4 to 0.8 ± 0.2 µg/kg/min) to restore MAP. Sodium ascorbate at 3.0 g/kg (achieving plasma ascorbate levels of ~ 10 mmol/L) rapidly restored MAP, allowing withdrawal of norepinephrine in half the animals (P = 0.007). Lower doses of sodium ascorbate (1.0 and 2.0 g/kg) had no significant effect on vasopressor requirements. The improvements in renal medullary oxygenation (25.2 ± 3.3 to 43.4 ± 4.5 mmHg, P = 0.04) and urine flow (from 0.5 ± 0.2 to 6.9 ± 2.4 ml/kg/h, P < 0.0001) were dose-dependent. Renal medullary tissue protein expression of nuclear factor kappa-light chain-enhancer B was significantly reduced with 3.0 g/kg of sodium ascorbate (to -52.9 ± 13.3%, P = 0.0005) and phosphorylated endothelial nitric oxide synthase at Ser-1177 was upregulated (to +219.5 ± 51.4%, P = 0.04) compared with vehicle-treated sheep.
Conclusions:
In established ovine Gram-negative sepsis, only 3.0 g/kg sodium ascorbate effectively restored cardiovascular and renal dysfunction, which was associated with suppression of renal inflammatory signalling and restoration of endothelial nitric oxide activity. These findings demonstrate a clear dose-dependent therapeutic threshold, where achieving plasma ascorbate concentrations of ~ 10 mmol/L is essential to elicit multi-organ protection.
More Related Videos
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
10:13Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury VI: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction